Type 2 Transglutaminase in Coeliac Disease: A Key Player in Pathogenesis, Diagnosis and Therapy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jul 27

PMID 35886862

Authors

Gaetana Paolella

Silvia Sposito

Antonio Massimiliano Romanelli

Ivana Caputo

Affiliations

Soon will be listed here.

Abstract

Type 2 transglutaminase (TG2) is the main autoantigen in coeliac disease (CD), a widespread inflammatory enteropathy caused by the ingestion of gluten-containing cereals in genetically predisposed individuals. As a consequence, serum antibodies to TG2 represent a very useful marker in CD diagnosis. However, TG2 is also an important player in CD pathogenesis, for its ability to deamidate some Gln residues of gluten peptides, which become more immunogenic in CD intestinal mucosa. Given the importance of TG2 enzymatic activities in CD, several studies have sought to discover specific and potent inhibitors that could be employed in new therapeutical approaches for CD, as alternatives to a lifelong gluten-free diet. In this review, we summarise all the aspects regarding TG2 involvement in CD, including its enzymatic reactions in pathogenesis, the role of anti-TG2 antibodies in disease management, and the exploration of recent strategies to reduce deamidation or to use transamidation to detoxify gluten.

Citing Articles

Celiac Disease: Beyond Diet and Food Awareness.

Herrera-Quintana L, Navajas-Porras B, Vazquez-Lorente H, Hinojosa-Nogueira D, Corrales-Borrego F, Lopez-Garzon M Foods. 2025; 14(3).

PMID: 39941971 PMC: 11817883. DOI: 10.3390/foods14030377.

Rapid discovery of Transglutaminase 2 inhibitors for celiac disease with boosting ensemble machine learning.

Wichka I, Lai P Comput Struct Biotechnol J. 2024; 23:3669-3679.

PMID: 39498152 PMC: 11532751. DOI: 10.1016/j.csbj.2024.10.019.

The Humoral Immune Response against Human Endogenous Retroviruses in Celiac Disease: A Case-Control Study.

Bo M, Manetti R, Biggio M, Sechi L Biomedicines. 2024; 12(8).

PMID: 39200275 PMC: 11351412. DOI: 10.3390/biomedicines12081811.

From an understanding of etiopathogenesis to novel therapies-what is new in the treatment of celiac disease?.

Skoracka K, Hryhorowicz S, Tovoli F, Raiteri A, Rychter A, Slomski R Front Pharmacol. 2024; 15:1378172.

PMID: 38698821 PMC: 11063403. DOI: 10.3389/fphar.2024.1378172.

Conformational Modulation of Tissue Transglutaminase via Active Site Thiol Alkylating Agents: Size Does Not Matter.

Navals P, Rangaswamy A, Kasyanchyk P, Berezovski M, Keillor J Biomolecules. 2024; 14(4).

PMID: 38672511 PMC: 11048362. DOI: 10.3390/biom14040496.

References

Barone M, Gimigliano A, Castoria G, Paolella G, Maurano F, Paparo F . Growth factor-like activity of gliadin, an alimentary protein: implications for coeliac disease. Gut. 2006; 56(4):480-8. PMC: 1856836. DOI: 10.1136/gut.2005.086637. View

Sollid L, Molberg O, McAdam S, Lundin K . Autoantibodies in coeliac disease: tissue transglutaminase--guilt by association?. Gut. 1998; 41(6):851-2. PMC: 1891617. DOI: 10.1136/gut.41.6.851. View

Voisine J, Abadie V . Interplay Between Gluten, HLA, Innate and Adaptive Immunity Orchestrates the Development of Coeliac Disease. Front Immunol. 2021; 12:674313. PMC: 8206552. DOI: 10.3389/fimmu.2021.674313. View

Ladinser B, Rossipal E, Pittschieler K . Endomysium antibodies in coeliac disease: an improved method. Gut. 1994; 35(6):776-8. PMC: 1374877. DOI: 10.1136/gut.35.6.776. View

Zanoni G, Navone R, Lunardi C, Tridente G, Bason C, Sivori S . In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med. 2006; 3(9):e358. PMC: 1569884. DOI: 10.1371/journal.pmed.0030358. View

Lammers K, Lu R, Brownley J, Lu B, Gerard C, Thomas K . Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008; 135(1):194-204.e3. PMC: 2653457. DOI: 10.1053/j.gastro.2008.03.023. View

Molberg O, McAdam S, Lundin K, Kristiansen C, Kett K, Sollid L . T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol. 2001; 31(5):1317-23. DOI: 10.1002/1521-4141(200105)31:5<1317::AID-IMMU1317>3.0.CO;2-I. View

Hadjivassiliou M, Reunala T, Hervonen K, Aeschlimann P, Aeschlimann D . TG6 Auto-Antibodies in Dermatitis Herpetiformis. Nutrients. 2020; 12(9). PMC: 7551372. DOI: 10.3390/nu12092884. View

Klock C, Diraimondo T, Khosla C . Role of transglutaminase 2 in celiac disease pathogenesis. Semin Immunopathol. 2012; 34(4):513-22. PMC: 3712867. DOI: 10.1007/s00281-012-0305-0. View

10.

Husby S, Koletzko S, Korponay-Szabo I, Kurppa K, Mearin M, Ribes-Koninckx C . European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. J Pediatr Gastroenterol Nutr. 2019; 70(1):141-156. DOI: 10.1097/MPG.0000000000002497. View

11.

Fesus L, Szondy Z . Transglutaminase 2 in the balance of cell death and survival. FEBS Lett. 2005; 579(15):3297-302. DOI: 10.1016/j.febslet.2005.03.063. View

12.

Durazzo M, Ferro A, Brascugli I, Mattivi S, Fagoonee S, Pellicano R . Extra-Intestinal Manifestations of Celiac Disease: What Should We Know in 2022?. J Clin Med. 2022; 11(1). PMC: 8746138. DOI: 10.3390/jcm11010258. View

13.

Agardh D, Matthias T, Wusterhausen P, Neidhofer S, Heller A, Lerner A . Antibodies against neo-epitope of microbial and human transglutaminase complexes as biomarkers of childhood celiac disease. Clin Exp Immunol. 2019; 199(3):294-302. PMC: 7008223. DOI: 10.1111/cei.13394. View

14.

Borrelli M, Maglio M, Korponay-Szabo I, Vass V, Mearin M, Meijer C . Intestinal anti-transglutaminase 2 immunoglobulin A deposits in children at risk for coeliac disease (CD): data from the PreventCD study. Clin Exp Immunol. 2017; 191(3):311-317. PMC: 5801494. DOI: 10.1111/cei.13078. View

15.

Paolella G, Lepretti M, Barone M, Nanayakkara M, Di Zenzo M, Sblattero D . Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects. Amino Acids. 2016; 49(3):541-550. DOI: 10.1007/s00726-016-2307-z. View

16.

Marino M, Casale R, Borghini R, Di Nardi S, Donato G, Angeloni A . The effects of modified versus unmodified wheat gluten administration in patients with celiac disease. Int Immunopharmacol. 2017; 47:1-8. DOI: 10.1016/j.intimp.2017.03.012. View

17.

Caio G, Volta U, Sapone A, Leffler D, De Giorgio R, Catassi C . Celiac disease: a comprehensive current review. BMC Med. 2019; 17(1):142. PMC: 6647104. DOI: 10.1186/s12916-019-1380-z. View

18.

Rauhavirta T, Hietikko M, Salmi T, Lindfors K . Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review. Clin Rev Allergy Immunol. 2016; 57(1):23-38. DOI: 10.1007/s12016-016-8557-4. View

19.

Kalliokoski S, Piqueras V, Frias R, Sulic A, Maatta J, Kahkonen N . Transglutaminase 2-specific coeliac disease autoantibodies induce morphological changes and signs of inflammation in the small-bowel mucosa of mice. Amino Acids. 2016; 49(3):529-540. DOI: 10.1007/s00726-016-2306-0. View

20.

Yi M, Melkonian A, Ousey J, Khosla C . Endoplasmic reticulum-resident protein 57 (ERp57) oxidatively inactivates human transglutaminase 2. J Biol Chem. 2018; 293(8):2640-2649. PMC: 5827427. DOI: 10.1074/jbc.RA117.001382. View